The South African variant of the coronavirus may require vaccines to be re-engineered to be effective. The warning comes from the National Institute for Communicable Diseases’ acting executive director, Adrian Puren, who told MyBroadband the 501.V2 variant that emerged in South Africa has undergone mutations that may affect antibody recognition and subsequently the vaccine, although this currently remains unclear. Puren says the NICD is also monitoring possible re-infections associated with the new variant.